SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 41.40 |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 17.20 |
| Book Value / Share | 1.10 |
| Price / Book | n/a |
| NCAV ($M) | 9.63 |
| NCAV / Share | 0.61 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -2.33 |
| Return on Assets (ROA) | -0.58 |
| Return on Equity (ROE) | -0.92 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.93 |
| Current Ratio | 1.93 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 32.39 |
| Assets | 39.96 |
| Liabilities | 22.76 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | 683 Capital Management, LLC | 6.10 | -86.99 | |
| 13G/A | Ridgeback Capital Investments L.P. | 9.90 | 15.34 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 33,744 | 177,864 | 18.97 | |
| 79,100 | 257,660 | 30.70 | |
| 65,406 | 331,025 | 19.76 | |
| 73,868 | 221,713 | 33.32 | |
| 32,726 | 109,468 | 29.90 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ACIU – AC Immune SA | ACRV – Acrivon Therapeutics, Inc. |
| ADMA – ADMA Biologics, Inc. | ALT – Altimmune, Inc. |
| ANIP – ANI Pharmaceuticals, Inc. |